Sammanfattning

Monoclonal antibody-based therapies have made an important contribution to current treatment strategies for cancer and autoimmune disease. However, the cost for these new drugs puts a significant strain on the health-care economy, resulting in limited availability for patients. Therapeutic vaccination, defined as induction of immunity against a disease-related self-molecule, is therefore an attractive alternative. To analyze the potential of such an approach, we have developed a vaccine against the extra domain-B (ED-B) of fibronectin. This 91-aa domain, inserted by alternative splicing, is expressed during vasculogenesis in the embryo, but essentially undetectable under normal conditions in the adult. However, ED-B is highly expressed around angiogenic vasculature, such as in tumorigenesis. Here, we demonstrate that it is possible to break self-tolerance and induce a strong antibody response against ED-B by vaccination. Nineteen of 20 vaccinated mice responded with production of anti-ED-B antibodies and displayed a 70% reduction in tumor size compared to those lacking anti-ED-B antibodies. Analysis of the tumor tissue revealed that immunization against ED-B induced several changes, consistent with an attack by the immune system. These data show that tumor vascular antigens are highly interesting candidates for development of therapeutic vaccines targeting solid tumors.-Huijbers, E. J. M., Ringvall, M., Femel, J., Kalamajski, S., Lukinius, A., Abrink, M., Hellman, L., Olsson, A.-K. Vaccination against the extra domain-B of fibronectin as a novel tumor therapy. FASEB J. 24, 4535-4544 (2010). www.fasebj.org

Nyckelord

therapeutic; immunization; neovascularization; extracellular matrix; angiogenesis

Publicerad i

FASEB Journal
2010, Volym: 24, nummer: 11, sidor: 4535-4544
Utgivare: FEDERATION AMER SOC EXP BIOL

UKÄ forskningsämne

Immunologi inom det medicinska området


Publikationens identifierare

DOI: https://doi.org/10.1096/fj.10-163022

Permanent länk till denna sida (URI)

https://res.slu.se/id/publ/41367